NasdaqGS:INGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. More Details

Rewards

Earnings are forecast to grow 30.93% per year

Risk Analysis

No risks detected for INGN from our risk checks.


Snowflake Analysis

Flawless balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Inogen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: INGN's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

3.5%

INGN

-1.5%

US Medical Equipment

2.1%

US Market


1 Year Return

-50.1%

INGN

16.3%

US Medical Equipment

19.8%

US Market

Return vs Industry: INGN underperformed the US Medical Equipment industry which returned 16.3% over the past year.

Return vs Market: INGN underperformed the US Market which returned 19.8% over the past year.


Shareholder returns

INGNIndustryMarket
7 Day3.5%-1.5%2.1%
30 Day28.0%-0.3%8.1%
90 Day22.2%2.7%6.0%
1 Year-50.1%-50.1%17.2%16.3%22.5%19.8%
3 Year-70.2%-70.2%67.0%62.7%46.5%36.8%
5 Year-8.6%-8.6%139.1%120.8%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is Inogen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inogen undervalued compared to its fair value and its price relative to the market?

2.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: INGN ($36.71) is trading above our estimate of fair value ($4.13)

Significantly Below Fair Value: INGN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: INGN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: INGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INGN is good value based on its PB Ratio (2.3x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Inogen forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

30.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: INGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: INGN's is expected to become profitable in the next 3 years.

Revenue vs Market: INGN's revenue (8.5% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: INGN's revenue (8.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: INGN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Inogen performed over the past 5 years?

6.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INGN is currently unprofitable.

Growing Profit Margin: INGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INGN is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.

Accelerating Growth: Unable to compare INGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).


Return on Equity

High ROE: INGN has a negative Return on Equity (-0.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is Inogen's financial position?


Financial Position Analysis

Short Term Liabilities: INGN's short term assets ($303.4M) exceed its short term liabilities ($52.0M).

Long Term Liabilities: INGN's short term assets ($303.4M) exceed its long term liabilities ($55.9M).


Debt to Equity History and Analysis

Debt Level: INGN is debt free.

Reducing Debt: INGN has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.

Debt Coverage: INGN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: INGN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Inogen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.8yrs

Average management tenure


CEO

Scott Wilkinson (55 yo)

3.67yrs

Tenure

US$2,520,530

Compensation

Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc. ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD2.52M) is about average for companies of similar size in the US market ($USD2.56M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Scott Wilkinson
CEO, President & Director3.67yrsUS$2.52m0.14%
$ 1.1m
Brenton Taylor
Co-founder & Executive VP of Engineering19.83yrsUS$845.76k0.26%
$ 2.1m
Alison Bauerlein
Co-founder19.83yrsUS$1.17m0.15%
$ 1.2m
Byron Myers
Founder & Executive Vice President of Marketing19.83yrsUS$876.82k0.17%
$ 1.3m
Bart Sanford
Executive Vice President of Operations2.17yrsUS$1.07m0.020%
$ 158.1k
Matthew Bacso
Investor Relations & Corporate Development Managerno datano datano data
Arron Retterer
Executive Vice President of Sales0.25yrno datano data
Matthew Pigeon
Investor Relations Officerno datano datano data

11.8yrs

Average Tenure

41yo

Average Age

Experienced Management: INGN's management team is seasoned and experienced (11.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Wilkinson
CEO, President & Director3.67yrsUS$2.52m0.14%
$ 1.1m
Benjamin Anderson-Ray
Independent Director7.83yrsUS$235.02k0.036%
$ 288.7k
R. Greer
Independent Director5.25yrsUS$245.02k0.081%
$ 648.6k
Raymond Huggenberger
Director12.83yrsUS$225.02k0.047%
$ 371.4k
Heath Lukatch
Independent Chairman of the Board12.83yrsUS$310.02k0.025%
$ 197.9k
Richard Casaburi
Member of Advisory Boardno datano datano data
Jeffrey Kupperman
Member of Advisory Boardno datano datano data
Paul Selecky
Member of Advisory Boardno datano datano data
Neil MacIntyre
Member of Advisory Boardno datano datano data
Loren McFarland
Independent Director7.83yrsUS$235.02k0.020%
$ 161.8k
Robert Chatburn
Member of Advisory Boardno datano datano data
Heather Rider
Independent Director6.25yrsUS$245.02k0.029%
$ 233.9k

7.8yrs

Average Tenure

61yo

Average Age

Experienced Board: INGN's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Inogen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inogen, Inc.
  • Ticker: INGN
  • Exchange: NasdaqGS
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$798.447m
  • Shares outstanding: 22.12m
  • Website: https://www.inogen.com

Number of Employees


Location

  • Inogen, Inc.
  • 326 Bollay Drive
  • Goleta
  • California
  • 93117
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2014
6IODB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United S...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 23:50
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.